Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.67 |
| ▸ | BRAF | P15056 | 9/20 | 0.60 |
| ▸ | RAF1 | P04049 | 7/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.60 |
| ▸ | PLK4 | O00444 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 2/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | FYN | P06241 | 2/20 | 0.55 |
| ▸ | LYN | P07948 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.55 |
| ▸ | AXL | P30530 | 2/20 | 0.55 |
| ▸ | FRK | P42685 | 2/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.55 |
| ▸ | BLK | P51451 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651380 | 1.00 | KDR (0.67) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL14480928 | 0.91 | KDR (0.56) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL940461 | 0.87 | KDR (0.62) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL167964 | 0.87 | KDR (0.68) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL13648120 | 0.86 | RAF1 (0.64) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL177768 | 0.86 | RAF1 (0.55) | KDRBRAFRAF1EPHX2NFKB1 | |
| SCHEMBL28431898 | 0.86 | KDR (0.64) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL15573297 | 0.86 | KDR (0.64) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL18068294 | 0.86 | BRAF (0.67) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL177723 | 0.86 | KDR (0.57) | KDRBRAFRAF1EPHX2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119330934-A | Degradation agent of targeted Smurf1 protein, preparation method and application | 中国人民解放军军事科学院军事医学研究院 | 2025-01-21 | — | — | CN | claimed |
| US-11174230-B2 | (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide conjugates as potential anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-11-16 | — | — | US | claimed |
| CN-108794392-B | Method for synthesizing sorafenib by solid-state ball milling | 中国药科大学 | 2021-08-10 | — | — | CN | claimed |
| US-20210163413-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-06-03 | — | — | US | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-108409648-B | Preparation method of sorafenib tosylate related intermediate | 盐城师范学院 | 2020-06-09 | — | — | CN | claimed |
| EP-3405457-B1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL SCIENT IND RES (IN) | 2020-03-11 | — | — | EP | claimed |
| EP-3405457-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | Council of Scientific & Industrial Research (IN) | 2018-11-28 | — | — | EP | claimed |
| CN-105085388-B | A kind of synthetic method of Sorafenib intermediate | 合肥华方医药科技有限公司 | 2018-07-13 | — | — | CN | claimed |
| WO-2017125946-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-07-27 | — | — | WO | claimed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | claimed |
| EP-1866302-B1 | PYRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | claimed |
| US-7767696-B2 | Antitumor agents; tyrosine inhbitor; controllling kinase signal transduction | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | claimed |
| EP-2195286-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | Cipla Limited (IN) | 2010-06-16 | — | — | EP | claimed |
| EP-2142507-A1 | PROCESS FOR THE PREPARATION OF SORAFENIB AND SALTS THEREOF | Sicor, Inc. (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2009111061-A1 | PROCESS FOR THE PREPARATION OF SORAFENIB AND SALTS THEREOF | SICOR INC. (US) | 2009-09-11 | — | — | WO | claimed |
| WO-2009034308-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2009-03-19 | — | — | WO | claimed |
| US-20080207699-A1 | Pyrazole Derivatives | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | claimed |
| EP-4701635-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | Universitat De Barcelona (ES) | 2026-03-04 | — | — | EP | disclosed |
| CN-121293151-A | Preparation method of 4- (4-aminophenoxy) -N-methyl-2-pyridine carboxamide | 大连市友谊医院 | 2026-01-09 | — | — | CN | disclosed |
| CN-121293151-A | Preparation method of 4- (4-aminophenoxy) -N-methyl-2-pyridine carboxamide | 大连市友谊医院 | 2026-01-09 | — | — | CN | disclosed |
| EP-3500257-B1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250109120-A1 | INDOLINE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF TUMOR OR CELL PROLIFERATIVE AND FIBROSIS DISEASES | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-04-03 | — | — | US | disclosed |
| CN-119330934-A | Degradation agent of targeted Smurf1 protein, preparation method and application | 中国人民解放军军事科学院军事医学研究院 | 2025-01-21 | — | — | CN | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| CN-118948847-A | Sorafenib pharmaceutical composition and preparation method thereof | 杭州华东医药集团新药研究院有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024223907-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | UNIVERSITAT DE BARCELONA (ES) | 2024-10-31 | — | — | WO | disclosed |
| US-20240287081-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-08-29 | — | — | US | disclosed |
| EP-4157844-B1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-07-10 | — | — | EP | disclosed |
| US-20240139194-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2024-05-02 | — | — | US | disclosed |
| CN-117843566-A | Polysubstituted benzene derivative, composition and use thereof | 康迈迪森(北京)医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-117447395-A | Method for preparing sorafenib key intermediate by utilizing micro-channel continuous flow | 山东安弘制药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3345910-B1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | SHIN POONG PHARMACEUTICAL CO LTD (KR) | 2023-11-01 | — | — | EP | disclosed |
| EP-4260704-A1 | ANTIMICROBIAL COMPOSITIONS COMPRISING A PHENYL UREA COMPOUND AND A CIS-UNSATURATED FATTY ACID WITH 16 TO 22 CARBON ATOMS | National Taiwan University (TW) | 2023-10-18 | — | — | EP | disclosed |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4157844-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Centre national de la recherche scientifique (FR) | 2023-04-05 | — | — | EP | disclosed |
| CN-110950807-B | Biaryl compound, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-03-03 | — | — | CN | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022261352-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-109251170-B | Method for preparing pyridine-2-formamide by using 2-OP rectification residue | 盐城工学院 | 2022-10-04 | — | — | CN | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| CN-112004845-B | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device | 三菱瓦斯化学株式会社 | 2022-05-31 | — | — | CN | disclosed |
| CN-216592510-U | Drying device | 福建南方济民医药研发中心有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-111362871-B | Substituted pyridine-2-carboxamides and their use | 北京福元医药股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-112028814-B | Method for preparing amine compound based on novel catalytic Curtius rearrangement reaction | 南京大学 | 2022-03-15 | — | — | CN | disclosed |
| CN-108602837-B | Compound having platelet aggregation inhibitory effect, salt thereof, and composition for preventing or treating thrombotic diseases comprising same | 新丰制药株式会社 | 2022-02-11 | — | — | CN | disclosed |
| WO-2021239727-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-02 | — | — | WO | disclosed |
| US-11174230-B2 | (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide conjugates as potential anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-11-16 | — | — | US | disclosed |
| US-11174230-B2 | (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide conjugates as potential anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-11-16 | — | — | US | disclosed |
| US-20210277221-A1 | RESIN COMPOSITION, LAMINATE, SEMICONDUCTOR WAFER WITH RESIN COMPOSITION LAYER, SUBSTRATE FOR MOUNTING SEMICONDUCTOR WITH RESIN COMPOSITION LAYER AND SEMICONDUCTOR DEVICE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-09-09 | — | — | US | disclosed |
| CN-108794392-B | Method for synthesizing sorafenib by solid-state ball milling | 中国药科大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-108794392-B | Method for synthesizing sorafenib by solid-state ball milling | 中国药科大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-108047142-B | Heteroaryl compounds and uses thereof | 西建卡尔有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| CN-110204483-B | Novel crystal form of sorafenib tosylate and preparation method thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210163413-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-06-03 | — | — | US | disclosed |
| US-20210163413-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-06-03 | — | — | US | disclosed |
| EP-3786200-A1 | RESIN COMPOSITION, LAMINATE, RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR WAFER, SUBSTRATE FOR MOUNTING RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR, AND SEMICONDUCTOR DEVICE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-03-03 | — | — | EP | disclosed |
| CN-112028814-A | Method for preparing amine compound based on novel catalytic Curtius rearrangement reaction | 南京大学 | 2020-12-04 | — | — | CN | disclosed |
| CN-112004845-A | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer, and semiconductor device | 三菱瓦斯化学株式会社 | 2020-11-27 | — | — | CN | disclosed |
| CN-107573340-B | Preparation and application of 2-carbamoyl-4-aryl hetero pyridine compound | 江西科技师范大学 | 2020-11-24 | — | — | CN | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-10730886-B2 | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-08-04 | — | — | US | disclosed |
| CN-107129465-B | Aryl guanidine compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-06-19 | — | — | CN | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| CN-108409648-B | Preparation method of sorafenib tosylate related intermediate | 盐城师范学院 | 2020-06-09 | — | — | CN | disclosed |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| CN-110950807-A | Biaryl compound, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-04-03 | — | — | CN | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3405457-B1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL SCIENT IND RES (IN) | 2020-03-11 | — | — | EP | disclosed |
| EP-2852574-B1 | PROCESS FOR SORAFENIB TOSYLATE POLYMORPH III | HETERO RESEARCH FOUNDATION (IN) | 2020-02-05 | — | — | EP | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190300484-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF REGORAFENIB | NATCO PHARMA LTD (IN) | 2019-10-03 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| EP-3500257-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | Icahn School of Medicine at Mount Sinai (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| CN-104672129-B | A kind of preparation method of carbamide compounds | 广东东阳光药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-10144710-B2 | Process for the preparation of 4-[-({[4-choloro-3(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide and its polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-12-04 | — | — | US | disclosed |
| EP-3405457-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | Council of Scientific & Industrial Research (IN) | 2018-11-28 | — | — | EP | disclosed |
| EP-2519235-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-11-21 | — | — | EP | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-2361248-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-09-19 | — | — | EP | disclosed |
| US-20180251472-A1 | Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2018-09-06 | — | — | US | disclosed |
| EP-3345910-A1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | Shin Poong Pharmaceutical Co., Ltd. (KR) | 2018-07-11 | — | — | EP | disclosed |
| EP-2739143-B1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2739143-B1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2018-07-11 | — | — | EP | disclosed |
| CN-108250136-A | A kind of preparation method of Sorafenib Tosylate | 南京法恩化学有限公司 | 2018-07-06 | — | — | CN | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170247331-A1 | PROCESS FOR THE PREPARATION OF 4-[-(AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-08-31 | — | — | US | disclosed |
| WO-2017125946-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017125946-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017125941-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF REGORAFENIB | NATCO PHARMA LTD (IN) | 2017-07-27 | — | — | WO | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| CN-104402813-B | Novel method for synthesizing sorafenib | 哈药集团制药总厂 | 2017-05-10 | — | — | CN | disclosed |
| EP-2675274-B1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2675274-B1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| WO-2017039395-A1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | 신풍제약 주식회사 | 2017-03-09 | — | — | WO | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-3060550-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-31 | — | — | EP | disclosed |
| US-9409921-B2 | 2,4-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| CN-105801475-A | Method for preparing sorafenib tosylate | 华润双鹤利民药业（济南）有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105646341-A | Sorafenib compound | 杭州华东医药集团新药研究院有限公司 | 2016-06-08 | — | — | CN | disclosed |
| WO-2016051422-A2 | PROCESS FOR THE PREPARATION OF 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-04-07 | — | — | WO | disclosed |
| US-9296737-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| CN-105272911-A | Preparation method of sorafenib tosylate | SHANDONG LUOXIN PHARMACEUTICAL GROUP CO LTD | 2016-01-27 | — | — | CN | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-9212181-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| CN-105085388-A | Synthesis method for sorafenib intermediate | HEFEI HUAFANG PHARMACEUTICAL SCIENCES & TECHNOLOGY CO LTD | 2015-11-25 | — | — | CN | disclosed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9156789-B2 | Process for sorafenib tosylate polymorph III | HETERO RESEARCH FOUNDATION (IN) | 2015-10-13 | — | — | US | disclosed |
| EP-2922820-A1 | PROCESS FOR PREPARING CRYSTALLINE SORAFENIB TOSYLATE | Shilpa Medicare Limited (IN) | 2015-09-30 | — | — | EP | disclosed |
| EP-2896620-A1 | ALKYNYL HETEROAROMATIC RING COMPOUND AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-07-22 | — | — | EP | disclosed |
| CN-104710354-A | High-purity sorafenib preparation method | JIANGSU HANSOH PHARMACEUTICAL | 2015-06-17 | — | — | CN | disclosed |
| US-20150152088-A1 | ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| CN-104672129-A | Preparation method of urea compound | GUANGDONG HEC PHARMACEUTICAL | 2015-06-03 | — | — | CN | disclosed |
| US-20150133670-A1 | PROCESS FOR SORAFENIB TOSYLATE POLYMORPH III | HETERO RESEARCH FOUNDATION (IN) | 2015-05-14 | — | — | US | disclosed |
| CN-103724258-B | Preparation method of sorafenib | QILU PHARMACEUTICAL CO LTD | 2015-05-13 | — | — | CN | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
| US-20150111929-A1 | PROCESS FOR PREPARING CRYSTALLINE SORAFENIB TOSYLATE | SHILPA MEDICARE LTD (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111929-A1 | PROCESS FOR PREPARING CRYSTALLINE SORAFENIB TOSYLATE | SHILPA MEDICARE LTD (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111929-A1 | PROCESS FOR PREPARING CRYSTALLINE SORAFENIB TOSYLATE | SHILPA MEDICARE LTD (IN) | 2015-04-23 | — | — | US | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-2852574-A2 | PROCESS FOR SORAFENIB TOSYLATE POLYMORPH III | Hetero Research Foundation (IN) | 2015-04-01 | — | — | EP | disclosed |
| CN-104402813-A | Novel method for synthesizing sorafenib | HARBIN PHARMACEUTICAL GROUP CO LTD GENERAL PHARMACEUTICAL FACTORY | 2015-03-11 | — | — | CN | disclosed |
| WO-2015011659-A1 | CRYSTALLINE POLYMORPHIC FORMS OF REGORAFENIB AND PROCESSES FOR THE PREPARATION OF POLYMORPH I OF REGORAFENIB | DR. REDDYS LABORATORIES LIMITED (IN) | 2015-01-29 | — | — | WO | disclosed |
| US-8937088-B2 | Ureas for the treatment and prevention of cancer | ASTAR BIOTECH LLC (US) | 2015-01-20 | — | — | US | disclosed |
| EP-1797037-B1 | PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENYOXY}N-METHYLPYRIDINE-2-CARBOXAMIDE | BAYER HEALTHCARE LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-1797037-B1 | PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENYOXY}N-METHYLPYRIDINE-2-CARBOXAMIDE | BAYER HEALTHCARE LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| CN-104177292-A | Method for industrial production of sorafenib tosylate polymorphic form I | YITENG PHARMACEUTICAL TAIZHOU CO LTD | 2014-12-03 | — | — | CN | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140213574-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014089913-A1 | BICYCLIC COMPOUND FUNCTIONING AS TYROSINE KINASE INHIBITOR | 山东亨利医药科技有限责任公司 (CN) | 2014-06-19 | — | — | WO | disclosed |
| EP-2739143-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Flynn, Gary, A. (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-1973897-B1 | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders | BAYER IP GMBH (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| CN-103724259-A | Synthesis method for sorafenib | JIANGSU JIXIAN GREEN CHEMICAL TECHNOLOGY RES INST CO LTD | 2014-04-16 | — | — | CN | disclosed |
| CN-103724258-A | Preparation method of sorafenib | QILU PHARMACEUTICAL CO LTD | 2014-04-16 | — | — | CN | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1641759-B1 | MALONAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-8618305-B2 | Sorafenib dimethyl sulphoxide solvate | RANBAXY LABORATORIES LIMITED (IN) | 2013-12-31 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2675274-A1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | The Regents of the University of California (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8614329-B2 | Polymorphs of sorafenib acid addition salts | RANBAXY LABORATORIES LIMITED (IN) | 2013-12-24 | — | — | US | disclosed |
| US-8609679-B2 | 2,4-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2013175483-A1 | PROCESS FOR PREPARING CRYSTALLINE SORAFENIB TOSYLATE | SHILPA MEDICARE LIMITED (IN) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013175506-A2 | PROCESS FOR SORAFENIB TOSYLATE POLYMORPH III | HETERO RESEARCH FOUNDATION (IN) | 2013-11-28 | — | — | WO | disclosed |
| EP-2661434-A1 | NOVEL UREAS FOR THE TREATMENT AND PREVENTION OF CANCER | Beta Pharma Canada Inc. (CA) | 2013-11-13 | — | — | EP | disclosed |
| US-8580798-B2 | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20130296380-A1 | Novel Ureas for the Treatment and Prevention of Cancer | BETA PHARMA CANADA INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| US-8552197-B2 | Sorafenib ethylsulfonate salt, process for preparation and use | RANBAXY LABORATORIES LIMITED (IN) | 2013-10-08 | — | — | US | disclosed |
| EP-2321298-B1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2321298-B1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130225641-A1 | ANTICANCER COMPOUNDS AND PREPARATION METHODS THEREOF | SUZHOU MAIDIXIAN PHARMACEUTICAL INC, (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225641-A1 | ANTICANCER COMPOUNDS AND PREPARATION METHODS THEREOF | SUZHOU MAIDIXIAN PHARMACEUTICAL INC, (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130210865-A1 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-15 | — | — | US | disclosed |
| EP-1478358-B1 | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis | BAYER HEALTHCARE LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8450335-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2013022766-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013022766-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20130005777-A1 | SORAFENIB ETHYLSULFONATE SALT, PROCESS FOR PREPARATION AND USE | RANBAXY LABORATORIES LIMITED (IN) | 2013-01-03 | — | — | US | disclosed |
| US-8338439-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2528899-A2 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE | Ranbaxy Laboratories Limited (IN) | 2012-12-05 | — | — | EP | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2519235-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2499116-A1 | SORAFENIB ETHYLSULFONATE SALT, PROCESS FOR PREPARATION AND USE | Ranbaxy Laboratories Limited (IN) | 2012-09-19 | — | — | EP | disclosed |
| CN-102675198-A | Method for preparing and purifying 4-(4-amino-phenoxy)-N-methylpyridine-2-formamide | ZHEJIANG HUAHAI PHARM CO LTD | 2012-09-19 | — | — | CN | disclosed |
| CN-102675198-A | Method for preparing and purifying 4-(4-amino-phenoxy)-N-methylpyridine-2-formamide | ZHEJIANG HUAHAI PHARM CO LTD | 2012-09-19 | — | — | CN | disclosed |
| WO-2012112570-A1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-23 | — | — | WO | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2478361-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | Avila Therapeutics, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012094451-A1 | NOVEL UREAS FOR THE TREATMENT AND PREVENTION OF CANCER | BETA PHARMA CANADA INC. (CA) | 2012-07-12 | — | — | WO | disclosed |
| US-8217061-B2 | crystalline Sorafenib tosylate | SICOR INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012071425-A1 | SOLID STATE FORMS OF SORAFENIB BESYLATE, AND PROCESSES FOR PREPARATIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-05-31 | — | — | WO | disclosed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8124782-B2 | Reacting aminophenoxy-N-methylpyridine-2-carboxamide with 4-chloro-3-trifluoromethylphenyl isocyanate in solvent; mixing; controlling temperature; mixing with p-toluenesulfonic acid; refluxing | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124782-B2 | Reacting aminophenoxy-N-methylpyridine-2-carboxamide with 4-chloro-3-trifluoromethylphenyl isocyanate in solvent; mixing; controlling temperature; mixing with p-toluenesulfonic acid; refluxing | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124782-B2 | Reacting aminophenoxy-N-methylpyridine-2-carboxamide with 4-chloro-3-trifluoromethylphenyl isocyanate in solvent; mixing; controlling temperature; mixing with p-toluenesulfonic acid; refluxing | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| US-8101773-B2 | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| CN-102311384-A | Preparation method of sorafenib | XIANGZHEN BIOTECHNOLOGY CO LTD | 2012-01-11 | — | — | CN | disclosed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2134677-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2361248-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-1379507-B1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-1379507-B1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| WO-2011092663-A2 | 4-(4-{3-[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]UREIDO}PHENOXY)-N2-METHYLPYRIDINE-2-CARBOXAMIDE DIMETHYL SULPHOXIDE SOLVATE | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| EP-1866302-B1 | PYRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | disclosed |
| EP-2338488-A1 | Drug combinations with substituted diaryl ureas for the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011058522-A1 | SORAFENIB ETHYLSULFONATE SALT, PROCESS FOR PREPARATION AND USE | RANBAXY LABORATORIES LIMITED (IN) | 2011-05-19 | — | — | WO | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| EP-2321298-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | BAYER HEALTHCARE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | BAYER HEALTHCARE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | BAYER HEALTHCARE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011046991-A2 | CERTAIN SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046991-A2 | CERTAIN SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2289515-A2 | Combinations comprising a diaryl urea and an interferon | Bayer HealthCare LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2111401-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100298385-A1 | PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS | DU, XIAOMIN (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298385-A1 | PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS | DU, XIAOMIN (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298385-A1 | PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS | DU, XIAOMIN (CN) | 2010-11-25 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2231612-A1 | POLYMORPH FORM III OF SORAFENIB TOSYLATE, SORAFENIB TOSYLATE METHANOL SOLVATE AND SORAFENIB TOSYLATE ETHANOL SOLVATE, AND PROCESSES FOR PREPARATION THEREOF | Sicor, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-7767696-B2 | Antitumor agents; tyrosine inhbitor; controllling kinase signal transduction | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767696-B2 | Antitumor agents; tyrosine inhbitor; controllling kinase signal transduction | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767696-B2 | Antitumor agents; tyrosine inhbitor; controllling kinase signal transduction | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2195286-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | Cipla Limited (IN) | 2010-06-16 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20100081812-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2010028236-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1690853-B1 | Use of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-03-10 | — | — | EP | disclosed |
| WO-2010017240-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017240-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| EP-2142507-A1 | PROCESS FOR THE PREPARATION OF SORAFENIB AND SALTS THEREOF | Sicor, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-2134677-A2 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-2111401-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253913-A1 | Process for the preparation of sorafenib and salts thereof | SICOR INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253913-A1 | Process for the preparation of sorafenib and salts thereof | SICOR INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2009111061-A1 | PROCESS FOR THE PREPARATION OF SORAFENIB AND SALTS THEREOF | SICOR INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192200-A1 | POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009092070-A1 | POLYMORPH FORM III OF SORAFENIB TOSYLATE, SORAFENIB TOSYLATE METHANOL SOLVATE AND SORAFENIB TOSYLATE ETHANOL SOLVATE, AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | RIEDL BERND | 2009-05-07 | — | — | US | disclosed |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | RIEDL BERND | 2009-05-07 | — | — | US | disclosed |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | RIEDL BERND | 2009-05-07 | — | — | US | disclosed |
| US-7528255-B2 | Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528255-B2 | Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| WO-2009054004-A2 | PROCESS FOR THE PREPARATION OF SORAFENIB | NATCO PHARMA LIMITED (IN) | 2009-04-30 | — | — | WO | disclosed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009034308-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034308-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2009-03-19 | — | — | WO | disclosed |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | BAYER PHARMACEUTICALS CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090069388-A1 | DEUTERIUM-ENRICHED SORAFENIB | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069388-A1 | DEUTERIUM-ENRICHED SORAFENIB | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080262236-A1 | Process for the Preparation of 4-Carbonyl)Amino]Phenoxy}-N-Methylpyridine-2-Carboxamide | BAYER HEALTHCARE AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262236-A1 | Process for the Preparation of 4-Carbonyl)Amino]Phenoxy}-N-Methylpyridine-2-Carboxamide | BAYER HEALTHCARE AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262236-A1 | Process for the Preparation of 4-Carbonyl)Amino]Phenoxy}-N-Methylpyridine-2-Carboxamide | BAYER HEALTHCARE AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| EP-1973897-A2 | SUBSTITUTED PYRYMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer HealthCare AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-20080234332-A1 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234332-A1 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234332-A1 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | disclosed |
| EP-1968589-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080207699-A1 | Pyrazole Derivatives | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207699-A1 | Pyrazole Derivatives | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207699-A1 | Pyrazole Derivatives | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | disclosed |
| WO-2008079968-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO] -3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079972-A2 | 4-{4- [ ({3-TERT-BUTYL-1- [3- (HYDROXYMETHYL) PHENYL] - 1H- PYRAZOL- 5 -YL } CARBAMOYL) -AMIN O] -3-CHLOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153823-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-06-26 | — | — | US | disclosed |
| US-20080153823-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-06-26 | — | — | US | disclosed |
| US-20080153823-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-06-26 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | disclosed |
| US-7351834-B1 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351834-B1 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351834-B1 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1158985-A4 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20080045589-A1 | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045589-A1 | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BAYER HEALTHCARE LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BAYER HEALTHCARE LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BAYER HEALTHCARE LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2008000252-A1 | NEW UREA DERIVATIVES AND THE APPLICATION THEREOF | SCHEBO BIOTECH AG (DE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007139930-A2 | DRUG COMBINATIONS WITH SUBSTITUTED DIARYL UREAS FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070213374-A1 | Malonamide Derivatives | MERCK PATENT GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213374-A1 | Malonamide Derivatives | MERCK PATENT GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| EP-1824843-A2 | INHIBITORS OF PROTEIN KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| WO-2007075650-A2 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1797037-A1 | PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENYOXY}N-METHYLPYRIDINE-2-CARBOXAMIDE | Bayer HealthCare AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2007053574-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| EP-1379505-B1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006113089-A2 | DIAGNOSIS BY DETERMINATION OF HYPERACTIVITY OR INCREASED EXPRESSION OF MEMBERS OF CELL SIGNALING PATHWAYS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060233705-A1 | Diagnosis by determination of hyperactivity or increased expression of members of cell signaling pathways | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-10-19 | — | — | US | disclosed |
| EP-1689722-A2 | 4-AMINOPYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1690853-A1 | W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | Bayer Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006062984-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| WO-2006034796-A1 | PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2006-04-06 | — | — | WO | disclosed |
| EP-1636585-A2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1140840-B1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1620109-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER HEALTHCARE LLC | 2006-01-26 | — | — | US | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1608639-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-15 | — | — | US | disclosed |
| EP-1603879-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005035507-A2 | 4-AMINOPYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2004113274-A2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1478358-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-18 | — | — | US | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096234-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004078748-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078128-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-1379507-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379505-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030207872-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-20030207870-A1 | Aryl ureas with angiogenisis inhibiting activity | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-20030181442-A1 | Carbamides such as N-(3-tert-butylphenyl)-N'-(4-(3-(N-methyl-carbamoyl)phenoxy)phenyl urea, used as enzyme inhibitors and as anticarcinogenic agents | BAYER CORPORATION | 2003-09-25 | — | — | US | disclosed |
| WO-2003068228-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| US-20030144278-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20030139605-A1 | Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors | BAYER HEALTHCARE LLC | 2003-07-24 | — | — | US | disclosed |
| US-20030105091-A1 | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC | 2003-06-05 | — | — | US | disclosed |
| US-20020165394-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER CORPORATION | 2002-11-07 | — | — | US | disclosed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085857-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020137774-A1 | Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002062763-A2 | INHIBITION OF RAF KINASE USING QUINOLYL ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | disclosed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153823-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BRAF, RAF1, ARAF | KDR 567/4885BRAF 1/4885RAF1 2/4885 |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885BRAF 2009/4885RAF1 4049/4885 |
| US-20180251472-A1 | Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same | PLA2G7, JAK2, PF4 | KDR 2936/4885BRAF 3622/4885RAF1 1973/4885 |
| US-20030181442-A1 | Carbamides such as N-(3-tert-butylphenyl)-N'-(4-(3-(N-methyl-carbamoyl)phenoxy)phenyl urea, used as enzyme inhibitors and as anticarcinogenic agents | NRAS, BRAF, RAF1 | KDR 3100/4885BRAF 2/4885RAF1 3/4885 |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | CCNC, UACA, SLC14A1 | KDR 502/4885BRAF 501/4885RAF1 1822/4885 |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | KDR 706/4885BRAF 19/4885RAF1 16/4885 |
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | KDR 532/4885BRAF 1/4885RAF1 2/4885 |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | KDR 706/4885BRAF 19/4885RAF1 16/4885 |
| US-20130210865-A1 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE | SRMS, SRM, BRAF | KDR 18/4885BRAF 3/4885RAF1 109/4885 |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885BRAF 2009/4885RAF1 4049/4885 |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | KDR 973/4885BRAF 141/4885RAF1 93/4885 |
| US-20240139194-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | KDR 308/4885BRAF 49/4885RAF1 95/4885 |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 843/4885BRAF 1/4885RAF1 2/4885 |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | KDR 533/4885BRAF 78/4885RAF1 352/4885 |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BRAF, RAF1, ARAF | KDR 567/4885BRAF 1/4885RAF1 2/4885 |
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | TP53, DOT1L, VHL | KDR 1343/4885BRAF 92/4885RAF1 1080/4885 |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | KDR 308/4885BRAF 49/4885RAF1 95/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | KDR 2667/4885BRAF 691/4885RAF1 925/4885 |
| US-10144710-B2 | Process for the preparation of 4-[-({[4-choloro-3(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide and its polymorphs thereof | CYP4X1, CYP4B1, CYP4F12 | KDR 4062/4885BRAF 3527/4885RAF1 4071/4885 |
| US-10730886-B2 | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | PLA2G7, JAK2, PF4 | KDR 2936/4885BRAF 3622/4885RAF1 1973/4885 |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | CDK4, MKI67, TP53 | KDR 135/4885BRAF 154/4885RAF1 761/4885 |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | KDR 706/4885BRAF 19/4885RAF1 16/4885 |
| US-20190300484-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF REGORAFENIB | KRAS, NRAS, HRAS | KDR 91/4885BRAF 4/4885RAF1 15/4885 |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BRAF, NRAS, RAF1 | KDR 192/4885BRAF 1/4885RAF1 3/4885 |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 611/4885BRAF 1/4885RAF1 2/4885 |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | KDR 993/4885BRAF 39/4885RAF1 49/4885 |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | KDR 706/4885BRAF 19/4885RAF1 16/4885 |
| US-20020165394-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BRAF, RAF1, ARAF | KDR 1324/4885BRAF 1/4885RAF1 2/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | KDR 624/4885BRAF 1/4885RAF1 3/4885 |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | EPHX1, FAH, EPHX2 | KDR 53/4885BRAF 12/4885RAF1 55/4885 |
| US-20020137774-A1 | Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, NRAS | KDR 609/4885BRAF 1/4885RAF1 2/4885 |
| US-20030207870-A1 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | KDR 3/4885BRAF 487/4885RAF1 867/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885BRAF 2009/4885RAF1 4049/4885 |
| US-20170247331-A1 | PROCESS FOR THE PREPARATION OF 4-[-(AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND ITS POLYMORPHS THEREOF | CYP3A4, CYP4F2, CYP4B1 | KDR 3769/4885BRAF 1666/4885RAF1 2861/4885 |
| US-20060233705-A1 | Diagnosis by determination of hyperactivity or increased expression of members of cell signaling pathways | GRK2, GRK4, CRHBP | KDR 3222/4885BRAF 318/4885RAF1 299/4885 |
| US-20130005777-A1 | SORAFENIB ETHYLSULFONATE SALT, PROCESS FOR PREPARATION AND USE | BRAF, ETV6, SF3B1 | KDR 33/4885BRAF 1/4885RAF1 7/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | KDR 1131/4885BRAF 3265/4885RAF1 2768/4885 |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | KDR 3/4885BRAF 487/4885RAF1 867/4885 |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | KDR 308/4885BRAF 49/4885RAF1 95/4885 |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AURKC, AURKA, CDK1 | KDR 538/4885BRAF 259/4885RAF1 230/4885 |
| US-20080262236-A1 | Process for the Preparation of 4-Carbonyl)Amino]Phenoxy}-N-Methylpyridine-2-Carboxamide | PNMT, TET2, TET3 | KDR 1119/4885BRAF 1178/4885RAF1 2887/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | KDR 44/4885BRAF 31/4885RAF1 51/4885 |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | MAPK1, MAPK8, MAPK3 | KDR 2141/4885BRAF 344/4885RAF1 452/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | KDR 499/4885BRAF 33/4885RAF1 100/4885 |
| US-20080207699-A1 | Pyrazole Derivatives | TIE1, FER, RAF1 | KDR 6/4885BRAF 8/4885RAF1 3/4885 |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K19 | KDR 960/4885BRAF 163/4885RAF1 37/4885 |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | TP53, MGMT, VHL | KDR 2208/4885BRAF 110/4885RAF1 880/4885 |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | PIK3CA, PNKP, PIK3CB | KDR 860/4885BRAF 378/4885RAF1 320/4885 |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TYMP, DPYD, CCNA2 | KDR 1618/4885BRAF 90/4885RAF1 183/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885BRAF 2009/4885RAF1 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.